Laigo Bio raises €11.5 million in seed financing to advance its SureTAC™ targeted protein degradation candidates in oncology and auto-immunity
Summary
Laigo Bio has raised €11.5 million in seed financing to advance its SureTAC platform for targeted protein degradation. The company will use the capital to push oncology programs toward clinical development and to expand its immunology work in autoimmune disease and graft rejection. The round was co-led by Kurma Partners and Curie Capital, with participation from several European investors. Laigo Bio also named Matthew Baker as CEO. The company says its platform targets previously hard-to-drug membrane proteins with high selectivity and promising preclinical results.
Funding
Amount
$13.4M
Total raised
Date
December 3, 2025
Announcement date
Investors
Kurma Life Science Partners, Eurazeo, Curie Capital
Lead investors
Company
https://www.laigobio.com/en/
Funded company
Classifications
industries
No industries detected
applications
No applications detected
AskAI Classifications
Labels
No AI classifications detected